Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2022 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Nov 12, 2021
Slide 1: Investor Presentation Q2FY22
Investor Presentation Q2FY22 November 12, 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q2FY22 and H1FY22
Key Highlights of Q2FY22 and H1FY22 Strong growth in the India business and new product launches in US driving the performance • Revenue from Operations grew by 18.5% YoY during the quarter, with EBITDA margin of 22.3% and Net Profit growth of 15.3% YoY • India Business: Company’s secondary sales in
Slide 4: Key Financial Highlights – Q2FY22 (Consolidated)
Key Financial Highlights – Q2FY22 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 28,000 19,605 15,574 23,628 Q2FY21 Q2FY22 International sales 7,790 8,052 Q2FY21 Q2FY22 Q2FY21 Q2FY22
Slide 5: Key Financial Highlights – Q2FY22 (Consolidated)
Key Financial Highlights – Q2FY22 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 17,425 6,005 6,244 14,289 60.5% 62.2% 25.4% 22.3% Q2FY21 Q2FY22 Q2FY21 Q2FY22 PBT (before Minority Interest) PAT (after Minority Interest) 5,443 4,721 5,815 5,478 Q2FY21 Q2FY22
Slide 6: Key Financial Highlights – H1FY22 (Consolidated)
Key Financial Highlights – H1FY22 (Consolidated) All figures in ₹ mn Particulars (₹ mn) H1FY22 H1FY21 YoY growth Revenue from Operations 55,314 43,548 27.0% Gross Profit 33,791 26,870 25.8% Gross Profit margin 61.1% 61.7% EBITDA 12,172 11,222 8.5% EBITDA margin 22.0% 25.8% PBT 11,377 10,405 9.3% PBT
Slide 7: India Business
India Business India Business: Q2FY22 Sales of ₹ 19,605 million (25.9% YoY growth) • India sales contributed 70.9% to total sales in Q2FY22 • In H1FY22, the Company’s secondary sales grew by 40.4% YoY compared to IPM growth of 26.4% YoY (Source: IQVIA data) • Growth was mainly led by acute therapies
Slide 8: Secondary Sales Performance
Secondary Sales Performance Robust growth across all the major therapeutic segments in Q2FY22 +2 Market rank 1 3 3 2 Acute Therapies 32.8% 30.6% 22.2% 21.9% 14.6% 16.0% 11.6% 8.2% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growth YoY1,2 Indian pharm
Slide 9: US Business
US Business US Business: Q2FY22 Sales of ₹ 6,097 million (YoY decline of 2.6%) • US sales contributed 22.0% to total sales in Q2FY22 • During the quarter, the US business registered sequential growth of 0.9% over Q1FY22. Significant pricing pressure on the base business was offset by new product lau
Slide 10: US Business – Update on US FDA inspections
US Business Update on US FDA inspections Manufacturing Capability Last inspection Status post last inspection Facility Received 2 observations. Already sent a detail response to the St. Louis (US) Formulations June 2021 US FDA on the corrective and preventive actions being taken Baddi (India) Formul
Slide 11: Other International Business
Other International Business Other International Business: Q2FY22 Sales of ₹ 1,954 million (27.5% YoY growth) • Other International Market sales contributed 7.1% to total sales in Q2FY22 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key markets lik
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on September 30, 2021 Non-Institution, 21.84% Promoter & Promoter Group, 58.84% Institution, 19.32% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other
Slide 13: Thank You
Thank You For further information or queries, please contact Gagan Borana Investor Relations Tel: +91 22 3982 9960 E-mail: [email protected]